MA56549A - Méthode de traitement d'une tumeur maligne - Google Patents
Méthode de traitement d'une tumeur maligneInfo
- Publication number
- MA56549A MA56549A MA056549A MA56549A MA56549A MA 56549 A MA56549 A MA 56549A MA 056549 A MA056549 A MA 056549A MA 56549 A MA56549 A MA 56549A MA 56549 A MA56549 A MA 56549A
- Authority
- MA
- Morocco
- Prior art keywords
- treating
- malignant tumor
- malignant
- tumor
- Prior art date
Links
- 201000011510 cancer Diseases 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5365—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2019115496 | 2019-06-21 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MA56549A true MA56549A (fr) | 2022-04-27 |
Family
ID=74040503
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MA056549A MA56549A (fr) | 2019-06-21 | 2020-06-19 | Méthode de traitement d'une tumeur maligne |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US20220354858A1 (fr) |
| EP (1) | EP3988175A4 (fr) |
| JP (1) | JP7574184B2 (fr) |
| KR (1) | KR20220024821A (fr) |
| AU (1) | AU2020297166A1 (fr) |
| MA (1) | MA56549A (fr) |
| TW (1) | TWI856115B (fr) |
| WO (1) | WO2020256096A1 (fr) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11883404B2 (en) | 2016-03-04 | 2024-01-30 | Taiho Pharmaceuticals Co., Ltd. | Preparation and composition for treatment of malignant tumors |
| EP3424505A4 (fr) | 2016-03-04 | 2019-10-16 | Taiho Pharmaceutical Co., Ltd. | Préparation et composition de traitement de tumeurs malignes |
| JP6918204B2 (ja) | 2018-03-19 | 2021-08-11 | 大鵬薬品工業株式会社 | アルキル硫酸ナトリウムを含む医薬組成物 |
| EP4284378A4 (fr) * | 2021-02-01 | 2024-12-25 | Taiho Pharmaceutical Co., Ltd. | Traitement du cancer chez un patient atteint d'une mutation d'inactivation de pten |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SG193327A1 (en) | 2011-04-06 | 2013-10-30 | Taiho Pharmaceutical Co Ltd | Novel imidazo-oxazine compound or salt thereof |
| MY171055A (en) | 2012-01-19 | 2019-09-23 | Taiho Pharmaceutical Co Ltd | 3,5-disubstituted alkynylbenzene compound and salt thereof |
| WO2014007217A1 (fr) * | 2012-07-02 | 2014-01-09 | 大鵬薬品工業株式会社 | Potentialisateur d'effet antitumoral composé d'un composé imidazooxazine |
| JP6289459B2 (ja) * | 2013-06-20 | 2018-03-07 | 大鵬薬品工業株式会社 | ＰＨＬＤＡ１又はＰＩＫ３Ｃ２Ｂの発現に基づくＰＩ３Ｋ／ＡＫＴ／ｍＴＯＲ阻害剤の治療効果の予測方法 |
| US10323044B2 (en) * | 2015-02-27 | 2019-06-18 | Taiho Pharmaceutical Co., Ltd. | Crystal of imidazo-oxazine, pharmaceutical composition containing said crystal, and method for producing said crystal |
| US11883404B2 (en) | 2016-03-04 | 2024-01-30 | Taiho Pharmaceuticals Co., Ltd. | Preparation and composition for treatment of malignant tumors |
| EP3424505A4 (fr) * | 2016-03-04 | 2019-10-16 | Taiho Pharmaceutical Co., Ltd. | Préparation et composition de traitement de tumeurs malignes |
| TW202140024A (zh) * | 2020-01-24 | 2021-11-01 | 日商大鵬藥品工業股份有限公司 | Shp2抑制劑嘧啶酮與新穎癌症醫藥併用於癌症之抗腫瘤活性之增強 |
| EP4284378A4 (fr) * | 2021-02-01 | 2024-12-25 | Taiho Pharmaceutical Co., Ltd. | Traitement du cancer chez un patient atteint d'une mutation d'inactivation de pten |
-
2020
- 2020-06-19 KR KR1020227002122A patent/KR20220024821A/ko not_active Withdrawn
- 2020-06-19 EP EP20827927.3A patent/EP3988175A4/fr active Pending
- 2020-06-19 AU AU2020297166A patent/AU2020297166A1/en not_active Abandoned
- 2020-06-19 US US17/620,419 patent/US20220354858A1/en active Pending
- 2020-06-19 MA MA056549A patent/MA56549A/fr unknown
- 2020-06-19 JP JP2021526910A patent/JP7574184B2/ja active Active
- 2020-06-19 TW TW109120904A patent/TWI856115B/zh active
- 2020-06-19 WO PCT/JP2020/024113 patent/WO2020256096A1/fr not_active Ceased
Also Published As
| Publication number | Publication date |
|---|---|
| WO2020256096A1 (fr) | 2020-12-24 |
| TW202114691A (zh) | 2021-04-16 |
| EP3988175A4 (fr) | 2023-06-28 |
| EP3988175A1 (fr) | 2022-04-27 |
| KR20220024821A (ko) | 2022-03-03 |
| JPWO2020256096A1 (fr) | 2020-12-24 |
| TWI856115B (zh) | 2024-09-21 |
| JP7574184B2 (ja) | 2024-10-28 |
| US20220354858A1 (en) | 2022-11-10 |
| AU2020297166A1 (en) | 2022-02-17 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MA56549A (fr) | Méthode de traitement d'une tumeur maligne | |
| EP3959218A4 (fr) | Promédicaments d'un inhibiteur de cdk pour le traitement de cancers | |
| EP3352761A4 (fr) | Méthode de traitement d'une tumeur rhabdoïde maligne de l'ovaire (mrto)/cancer à petites cellules de l'ovaire du type hypercalcémique (sccoht) avec un inhibiteur d'ezh2 | |
| MA56508A (fr) | Inhibiteur d'egfr pour le traitement du cancer | |
| EP3778649A4 (fr) | Méthode et composition de traitement de tumeurs | |
| MA54388A (fr) | Méthodes de traitement du cancer résistant aux inhibiteurs cdk4/6 | |
| EP4034128A4 (fr) | Méthode d'induction de régression tumorale | |
| EP3952858A4 (fr) | Procédé de traitement de tumeurs | |
| EP3782618A4 (fr) | Méthode pour prévenir ou traiter les effets secondaires d'une cancérothérapie | |
| MA47408B1 (fr) | Traitement du cancer | |
| EP3775171A4 (fr) | Procédés de traitement d'un cancer résiduel minimal | |
| IL285352A (en) | Anti-nme antibody and method of treating cancer or cancer metastasis | |
| EP3774785A4 (fr) | Méthode de traitement d'un trouble fibrotique | |
| EP3644062C0 (fr) | Procédé de prédiction de réponse d'un cancer de l' oesophage à une thérapie par anticorps anti-erbb3 | |
| EP3834849A4 (fr) | Procédé de traitement tumoral à l'aide d'une cellule effectrice immunitaire | |
| EP3672689A4 (fr) | Procédé de traitement d'une tumeur neuroendocrine | |
| MA54827A (fr) | Méthodes de traitement d'une maladie à l'aide d'inhibiteurs de magl | |
| EP3920895A4 (fr) | Procédé de prévention ou de traitement d'une lésion gastro-intestinale induite par un traitement | |
| IL289811A (en) | A method for treating cancer | |
| EP3810107A4 (fr) | Méthode pour traiter une maladie allergique | |
| SG11202107017TA (en) | Methods of treating cancer | |
| EP3412295A4 (fr) | Méthode de traitement de patients atteints de cancer souffrant d'insuffisance rénale grave | |
| EP3773693A4 (fr) | Méthode de traitement d'une maladie autoimmune | |
| EP4321868A4 (fr) | Méthode de traitement du cancer à l'aide d'un inhibiteur de point de contrôle immunitaire | |
| EP3958892A4 (fr) | Méthodes de traitement d'une maladie hépatique |